NCT06809062

Completed

ApoE Genotyping Analysis in Patients With Suspected Non-haem...

Centre Hospitalier Universitaire de Nīmes Source

Compare

Other study identifiers

Sponsor study identifier

LOCAL/2024/DR-04

Study Type

observational

Actual enrollment (reported)

100

Locations

1 country

Sites

1

Timeline

Study Start

February 1, 2025

Actual (reported)

Primary Completion

December 31, 2025

Actual (reported)

Study Completion

December 31, 2025

Actual (reported)

Brief Summary

Ischaemic microangiopathic features have recently been incorporated into the criteria for cerebral amyloid angiopathy (CAA). ApoE genotyping (presence of the E4 allele) is routinely used to help determine the aetiology of a haemorrhagic microangiopathy found on MRI. Chronic ischaemic disease in CAA is characterised by the presence of :

multispot pattern on the FLAIR sequence
severe periventricular FLAIR hypersignals with posterior predominance The main aim of this study was therefore to analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected CAA based on ischaemic MRI involvement with a typical radiological pattern.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 100 participants
Study completion date: December 31, 2025
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
January 24, 2025
Actual (reported)
Study Start
February 1, 2025
Actual (reported)
First Posted
February 5, 2025
Actual (reported)
Primary Completion
December 31, 2025
Actual (reported)
Study Completion
December 31, 2025
Actual (reported)

Last Updated: June 18, 2026
Status Verified: June 2026
Last Update Submitted: June 17, 2026

Conditions

Amyloid Angiopathy

Keywords

Cerebral Amyloid Angiopathy

Outcome Measures

Primary Outcomes (1)

ApoE genotypage
To analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected AAC. Endpoint: presence of the E4 allele (Yes/No).
baseline

Study Arms (1)

ischaemic microangiopathy

The study is aimed at patients with manifestations related to a vascular accident visible on MRI.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients with ischaemic stroke (from causes other than CAA, as CAA is not a frequent cause of ischaemic stroke) with associated stigmata of microangiopathy on MRI that may suggest associated CAA.

You may qualify if:

Patients with ischaemic stroke (from causes other than CAA, as CAA is not a frequent cause of ischaemic stroke) with associated stigmata of microangiopathy on MRI that may suggest associated CAA.

Sponsors & Collaborators

Centre Hospitalier Universitaire de Nīmes
Otherlead

Study Sites (1)

CHU de Nîmes

Nîmes, Gard, 30029, France

MeSH Terms

Conditions

Amyloid angiopathyCerebral Amyloid Angiopathy

Condition Hierarchy (Ancestors)

Cerebral Arterial DiseasesIntracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesAmyloidosisProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

Anissa MEGZARI
Centre Hospitalier Universitaire de Nīmes
STUDY DIRECTOR

Enrollment

100 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 24, 2025

First Posted

February 5, 2025

Study Start

February 1, 2025

Actual (reported)

Patients treated at Nîmes University Hospital

You may not qualify if:

Patient refusing to participate

Contact the study team to confirm eligibility.

Primary Completion

December 31, 2025

Actual (reported)

Study Completion

December 31, 2025

Actual (reported)

Last Updated

June 18, 2026

Record last verified: 2026-06

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT06809062
Data provider: ClinicalTrials.gov
Source updated: 2026-06-18
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:59 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

ischaemic microangiopathy

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations